New England Independent Review Board Joins the WIRB-Copernicus Group
New addition expands WCG's New England presence and increases its expertise in all phases of clinical research
WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that New England Independent Review Board (IRB) has joined the group of companies. Based near Boston, MA, New England IRB expands WCG’s presence in the important New England clinical research hub and further increases its expertise in all phases of drug, medical device and behavioral research.
WCG Chairman and CEO Donald A. Deieso, Ph.D., commented, “We are delighted to welcome New England IRB to the WCG family. New England IRB is recognized for its focus on quality – it has an exceptional regulatory and compliance record – and for providing extraordinary, personalized servicetoits customers.” He added, “The level of innovation and clinical research leadership in the New England region has grown substantially in the pharmaceutical and biotech industry. It is important that we provide a strong regional presence for our clients.”
Founded in 1988, New England IRB was one of the first national, central IRBs dedicated to ensuring the rights and welfare of research study participants.
“We are excited to begin this new phase in New England IRB’s growth,” said New England IRB President James Saunders. “We can now offer our clients access to technologies and processes that will make the clinical trial process more efficient.”
New England IRB will continue to operate independently and will retain its leadership, personnel, and brand. WCG will provide New England IRB with access to technologies, capital and corporate support.
New England IRB joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, and IRBNet as a member of the WCG family of companies. With the addition of New England IRB, WCG has 14 individual IRB panels, all accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), reviewing clinical research.
“Having maintained its AAHRPP accreditation since 2004, New England IRB has demonstrated itself as a very high quality review board,”said AAHRPP President and CEO Elyse Summers, J.D. “WCG’s commitment to human subjects’ protection and AAHRPP accreditation across its wide spectrum of clients redounds ultimately to the benefit of the volunteers who make the entire human research enterprise possible,” she added.
Financial details about the transaction were not disclosed.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
